Merck KGaA

News

Merck partners neuroloop on bioelectronic device for inflamm...

Merck KGaA has joined forces with a unit of medtech firm B Braun – neuroloop – on a way to treat inflammatory diseases using neurostimulator devices.

Views & Analysis

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ...

Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab.

News

NICE says no to Merck Serono's Bavencio in bladder cancer

Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to

News

MoonLake launches, licensing in Merck KGaA's Cosentyx challe...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KG

News

Avillion/Merck psoriasis nanobody hits the mark in phase 2

UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis' Cosenty

News

GSK’s big-ticket cancer alliance with Merck KGaA stumbles ag...

Merck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a few weeks, making GlaxoSmithKline’s $4.2 billion licensing deal for the drug lo

Merck partners neuroloop on bioelectronic device for inflamm...

Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ...

NICE says no to Merck Serono's Bavencio in bladder cancer

MoonLake launches, licensing in Merck KGaA's Cosentyx challe...

Avillion/Merck psoriasis nanobody hits the mark in phase 2

GSK’s big-ticket cancer alliance with Merck KGaA stumbles ag...

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Merck KGaA

Editor's Picks